Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
US gastroenterologists more in favor of biosimilars than rheumatology and dermatology counterparts. EXTON, PA., September 23, 2024 — Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April 2024 (n=104 gastroenterologists, 103 rheumatologists, and 106 dermatologists), to provide an updated perspective on adalimumab biosimilar […]
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
While reported use of Sanofi/Regeneron’s Dupixent has declined with the adoption of LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the overall population receiving advanced treatments is on the rise, according to Spherix Global Insights. EXTON, PA., September 9, 2024 — Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s […]
Evaluating the Efficacy and Perception of HS Treatment Options
Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab. Managing hidradenitis suppurativa (HS) effectively remains challenging for dermatology clinicians, necessitating innovative and effective treatment options. Recently, Spherix Global Insights took a deep dive into secukinumab (Cosentyx; Novartis) versus adalimumab (Humira; AbbVie) in HS treatment performance.1 […]
Amjevita leads Humira biosimilars in clinician comfort as rheumatologists remain wary
Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights. For reference, 83% of rheumatologists included in the analysis reported being “extremely comfortable” prescribing originator Humira (adalimumab, AbbVie). This yawning gap underscores […]
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks to the surprising resilience of AbbVie’s autoimmune blockbuster. Now, in the face of lackluster Cytelzo sales, Boehringer has decided to prune its ranks in the U.S. and adopt […]
Market Study Reports Secukinumab Emerged as a Leading Treatment for HS
To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than 100 US dermatologists. In a significant development for patients with hidradenitis suppurativa (HS), the FDA granted approval to secukinumab (Cosentyx, Novartis) last fall. This marked a milestone as secukinumab became the second biologic, alongside adalimumab […]
Novartis’ Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie’s Humira
Despite the expanded armamentarium, Cosentyx has not impacted dermatologists’ perceived unmet need for new HS treatment options, according to Spherix Global Insights. [Exton, PA., January 10, 2024] — In late October 2023, the FDA granted approval to Novartis’ Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the second biologic approved alongside AbbVie’s Humira […]
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
US dermatologists’ perceptions and experience with Sotyktu likely impacting their take on the entire TYK2 class for the treatment of plaque psoriasis. Exton, PA., December 7, 2023 – While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call, practicing dermatologists in Spherix research highlight […]
Majority of Dermatologists in US Prescribe Baricitinib to Patients With Alopecia Areata, Report Shows
Bariticinib (Olumiant; Eli Lilly) is prescribed by the majority of US dermatologists to their patients with alopecia areata (AA), according to a recent analysis (Market Dynamix: Alopecia Areata). Additionally, more than half of US dermatologists have begun trial of ritlecitinib (Litfulo; Pfizer) in their patients with AA. According to the analysis, 6-month market projections for […]
Eli Lilly’s Olumiant and Pfizer’s Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market lead over Litfulo. [Exton PA, November 15, 2023] — Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK inhibitors has […]
